Supplemental Material: Tolerability and Efficacy of Unorthodox Dosing Regimens of Tofacitinib and Baricitinib in Pediatric Patients with Moderate to Severe Alopecia Areata

This study evaluated the efficacy and tolerability of unorthodox weight-stratified dosing regimens of tofacitinib and baricitinib in pediatric patients aged 2–17 years with moderate-to-severe alopecia areata over 24 weeks. Both drugs demonstrated comparable overall efficacy and were well-tolerated, with no serious adverse events. However, the unorthodox twice-daily dosing of baricitinib showed reduced efficacy compared to the guideline-recommended once-daily regimen, suggesting that deviations from standard dosing may lead to suboptimal outcomes. The study suggests that unorthodox dosing could be a short-term alternative for patients who cannot tolerate standard doses, but it requires careful monitoring to ensure therapeutic effectiveness. Safety profiles were favorable, with mild adverse events and no increased risk of serious infections or cardiovascular events.